Emerging molecular and cellular therapeutics for type 2 diabetes: integrating stem cell and miRNA approaches toward precision medicine

Type 2 Diabetes (T2D) is a complex metabolic disorder marked by insulin resistance and a progressive loss of functional pancreatic β-cell mass. Despite major advances in pharmacotherapy, most current treatments focus on glycemic control rather than the underlying mechanisms of disease progression. Consequently, many patients experience worsening β-cell dysfunction over time, underscoring the need for disease-modifying strategies. Recent advances in regenerative medicine and RNA-based technologies offer new opportunities to target the mechanisms of T2D progression. This review examines emerging molecular and cellular therapeutics aimed at restoring β-cell health and improving metabolic regulation in T2D. We highlight limitations of conventional approaches and analyze two rapidly evolving strategies. First, stem cell-based therapies, including mesenchymal stem/stromal cells (MSCs) and pluripotent stem cell-derived β-cells, have shown preclinical potential to replenish insulin-producing cells and reshape the pancreatic microenvironment, though clinical evidence remains preliminary. Second, microRNA (miRNA) therapeutics, such as mimics and antagomirs, are designed to modulate dysregulated gene networks involved in insulin sensitivity, inflammation, and β-cell survival, but their translational application remains investigational. We also examine ongoing clinical trials, the potential synergy between these novel therapies and standard antidiabetic medications, and the role of multi-omics and artificial intelligence in enabling patient-specific strategies. However, it is critical to emphasize that no regenerative strategy has yet demonstrated durable disease modification or remission in T2D beyond short-term glycemic improvement. The convergence of these approaches provides a scientific roadmap for future investigation, but clinical implementation remains distant.